Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06609759
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-18
Brief Title:
Postoperative Adjuvant Therapy for Stage II-III Gastric Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Efficacy and Safety of Postoperative Adjuvant Therapy for Stage II-III Gastric Cancer a Prospective Observational Study
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
For patients with stage II-III gastric cancer after radical D2 resection and R0 resection postoperative adjuvant therapy guided by ctDNA-MRD MRD-GATE external cohort was not inferior to the standard chemotherapy regimen this cohort
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None